Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

por Raab, Marc S., Zamagni, Elena, Manier, Salomon, Rodriguez‐Otero, Paula, Schjesvold, Fredrik, Broijl, Annemiek
Publicado 2023

Is immunotherapy here to stay in multiple myeloma?

por Rodríguez-Otero, Paula, Paiva, Bruno, Engelhardt, Monika, Prósper, Felipe, San Miguel, Jesús F.
Publicado 2017

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time

por Rodríguez-Otero, Paula, Prósper, Felipe, Alfonso, Ana, Paiva, Bruno, Miguel, Jesús F. San
Publicado 2020

P951: IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) DIFFERENCES ON PROGRESSION-FREE SURVIVAL (PFS): AN AGGREGATE DATA ANALYSIS FROM RANDOMIZED CLINICAL TRIALS IN MULTIPLE MYELOMA (MM...

por Paiva, Bruno, Zherniakova, Anastasiia, Nuñez, Jorge, Rodríguez-Otero, Paula, Shi, Qian, Munshi, Nikhil, Durie, Brian, San Miguel, Jesús
Publicado 2023

Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?

por Rodriguez-Otero, Paula, Reis, Joana, Alfonso-Pierola, Ana, Salas-Benito, Diego, Giraldez, Miriam, Azanza, Jose Ramón, Ponz-Sarvise, Mariano
Publicado 2020

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

por Hungria, Vania, Piérola, Ana Alfonso, Filho, Jayr Schmidt, Crusoe, Edvan, Filho, Roberto José Pessoa de Magalhães, Maiolino, Angelo, Rodríguez-Otero, Paula
Publicado 2023

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

por Weisel, Katja, Bahlis, Nizar J, Rodríguez-Otero, Paula, Viqueira, Andrea, Wang, Shen-Wu, Sathiah, Sangeetha, Robinson, Douglas, O’brien, Thomas, Quach, Hang
Publicado 2023

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

por Rodríguez-Otero, Paula, Quach, Hang, Weisel, Katja, Viqueira, Andrea, Wang, Shen-Wu, Hamilton, Phineas T., Xie, Tao, O’brien, Thomas, Bahlis, Nizar J
Publicado 2023

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

por Mateos, Maria-Victoria, Bahlis, Nizar J, Spencer, Andrew, Kaedbey, Rayan, Rodríguez-Otero, Paula, Harrison, Simon, Wong, Chihunt, Goodman, Grant, Nakamura, Rin, Choeurng, Voleak, Cooper, James, Trudel, Suzanne
Publicado 2023

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

por Ocio, Enrique M., Bringhen, Sara, Martinez-Lopez, Joaquin, San-Miguel, Jesus, Oliva, Stefania, Rodriguez-Otero, Paula, Le Roux, Nadia, Dong, Yvonne, Doroumian, Severine, Macé, Sandrine, Mateos, Maria-Victoria
Publicado 2023

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

por San José-Enériz, Edurne, Román-Gómez, José, Jiménez-Velasco, Antonio, Garate, Leire, Martin, Vanesa, Cordeu, Lucia, Vilas-Zornoza, Amaia, Rodríguez-Otero, Paula, José Calasanz, María, Prósper, Felipe, Agirre, Xabier
Publicado 2009

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT...

por Lonial, Sagar, Quach, Hang, Dimopoulos, Meletios A., Rodríguez-Otero, Paula, Berdeja, Jesus, Richardson, Paul, Kyada, Margee, Chu, Shuyu, Chen, Min, Abad, Patricia, Morando, Juliane, van de Donk, Niels W.C.J.
Publicado 2023

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT...

por Weisel, Katja, Hungria, Vania, Quach, Hang, Yoon, Sung-Soo, Rodríguez-Otero, Paula, Kroog, Glenn, Sinha, Arijit, Boyapati, Anita, Lyon, Charlotte, Lorenc, Karen Rodriguez, Inocencio, Timothy, Harnett, James, Chi, Lei, Moore, Vygngley, Voorhees, Peter
Publicado 2023

(18)F-FDG and (11)C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers

por Morales-Lozano, Maria I, Viering, Oliver, Samnick, Samuel, Rodriguez-Otero, Paula, Buck, Andreas K, Marcos-Jubilar, Maria, Rasche, Leo, Prieto, Elena, Kortüm, K Martin, San-Miguel, Jesus, Garcia-Velloso, Maria J., Lapa, Constantin
Publicado 2020

(11)C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to (18)F-FDG PET/CT and Prognostic Value

por Morales-Lozano, Maria I., Rodriguez-Otero, Paula, Sancho, Lidia, Nuñez-Cordoba, Jorge M., Prieto, Elena, Marcos-Jubilar, Maria, Rosales, Juan J., Alfonso, Ana, Guillen, Edgar F., San-Miguel, Jesus, Garcia-Velloso, Maria J.
Publicado 2022

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

por Jagannath, Sundar, Lin, Yi, Goldschmidt, Hartmut, Reece, Donna, Nooka, Ajay, Senin, Alicia, Rodriguez-Otero, Paula, Powles, Ray, Matsue, Kosei, Shah, Nina, Anderson, Larry D., Streetly, Matthew, Wilson, Kimberly, Le, Hoa Van, Swern, Arlene S., Agarwal, Amit, Siegel, David S.
Publicado 2021

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL)...

por Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, Rodríguez-Otero, Paula
Publicado 2023

Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia

por Vilas–Zornoza, Amaia, Agirre, Xabier, Martín-Palanco, Vanesa, Martín-Subero, José Ignacio, San José-Eneriz, Edurne, Garate, Leire, Álvarez, Sara, Miranda, Estíbaliz, Rodríguez-Otero, Paula, Rifón, José, Torres, Antonio, Calasanz, María José, Cigudosa, Juan Cruz, Román-Gómez, José, Prósper, Felipe
Publicado 2011

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATIO...

por Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J, Rodríguez-Otero, Paula, Martinez-Lopez, Joaquín, Touzeau, Cyrille, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Manier, Salomon, Raje, Noopur, Raab, Marc S., Searle, Emma, Leip, Eric, Sullivan, Sharon T., Czibere, Akos, Viqueira, Andrea, Lesokhin, Alexander
Publicado 2023

P887: PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

por Tamariz-Amador, Luis-Esteban, Alfonso-Piérola, Ana, Huerga-Dominguez, Sofia, Panizo-Inoges, Maria, Palacios-Berraquero, Maria-Luisa, Roca, Jose Juan Rifon, Villar-Fernandez, Sara, Marcos Jubilar, Maria, Prosper, Felipe, Betech-Antar, Vicky, San Miguel, Jesús, Garcia-Velloso, Maria-Jose, Rodríguez-Otero, Paula
Publicado 2023